Clinical trial · Observational
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
NCT06202417CI-TRIAL-00072918completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Refractory Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fruquintinib | Drug | Fruquintinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- monotherapy group
- description
- patients received fruquintinib alone
- interventionNames
- Drug: Fruquintinib
- label
- combine group
- description
- patients administered fruquintinib in combination with chemotherapy or/and anti-PD1 antibodies
- interventionNames
- Drug: Fruquintinib
Primary outcomes (3)
- measure
- PFS
- timeFrame
- Three years
- description
- PFS was calculated from the date of fruquintinib administration to the first observation of disease progression or death
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: (1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data. Exclusion Criteria: (1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.
References
Publications (1)
- DERIVEDXu D, Zeng S, Qiu W, Wang G, Qin Z, Liu Y, Zhou S, Zhang Z, Chang W, Feng Q, Xu J. Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study. ESMO Open. 2024 Nov;9(11):103702. doi: 10.1016/j.esmoop.2024.103702. Epub 2024 Oct 11. PMID 39395266